FDA
-
-
-
-
-
-
-
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
-
-
-
-
-
-
-
NeuroPace reports Q4 revenue of $26.6 million, up 24% year-over-year
-
-
-
-
-
-
-
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
-
-
-
-
-
-
-
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
-
-
-
-
-
-
-
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
-
-
-
-
-
-
-
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
-
-
-
-
-
-
-
NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
-
330,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

